Loading quotes...

Forecast

The analysts' average price target is €51.13 (-6.18%). The median is €49.08 (-9.94%).

Buy
  18
Hold
  2
Sell
  0

  • AtriCure continues growth trajectory with focus on atrial fibrillation

    AtriCure is focusing on the treatment of atrial fibrillation and recorded a strong sector performance of 26.07%. Revenue rose 12.8% in the second quarter of 2026. The company is positioning itself as a leading provider in the Medical Instruments & Supplies segment and is addressing a global patient population of over 59 million. » More on finanzen.net


  • AtriCure reaches 52‑week high at $55.83

    AtriCure shares climbed to a new 52‑week high of $55.83, reflecting strong investor sentiment after a year‑to‑date rise of 59.75% and a six‑month gain of 82.74%. The medtech company reported revenue of $569.62 million (+13.94%) and in Q2 delivered adjusted earnings of $0.18 per share and revenue of $153.6 million, beating analysts' expectations. Despite the results, the stock fell in after‑hours trading on a cautious outlook; several banks raised their price targets, while InvestingPro data indicate potential overvaluation or that the stock is overbought. » More on de.investing.com


  • AtriCure exceeds long-term plan on growth and EBITDA margin

    At the Wells Fargo conference, AtriCure said revenue and adjusted EBITDA margin are increasing faster than planned, with the 2026 forecast already reaching the 14% margin that had originally been targeted for 2028. The company continues to prioritize organic growth but considers acquisitions possible and reports a cash balance of over $167 million. Key clinical programs (LEAPS, BoxX-NoAF) are progressing faster than expected and could significantly expand market potential; the product pipeline includes a PFA-/RF dual-energy technology and smaller AtriClip variants. Pain management is driving near-term growth, while hybrid ablations are lagging expectations and some international markets are showing execution issues. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2022, AtriCure has already paid €0.33 in dividends. The last payout was in October 2022.

Financials

In the last quarter, AtriCure had revenue of €134.59M and net profit of €7.85M
(EUR) June 2026
YoY
Revenue 134.59M 16.52%
Gross profit 103.94M 20.73%
Net profit 7.85M 249.41%
EBITDA 12.06M 1,841.92%

Fundamentals

Metric Value
Market capitalization
€2.78B
Number of shares
50.87M
52-week high/low
€56.22 - €22.63
Dividends No
Beta
1.25
P/E ratio
288.64
PEG ratio
0.24
P/B ratio
5.75
P/S ratio
5.47

Company profile

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Name
AtriCure
CEO
Michael H. Carrel
Headquarters Mason, oh
USA
Website
Sector
Consumer Discretionary
Industry
Household Durables
IPO
08/05/2005
Employees 1,350

Ticker symbols

Exchange Symbol
NASDAQ
ATRC
🍪

Parqet  uses cookies. Learn more